Show simple item record

dc.contributor.authorKerr, K M
dc.contributor.authorBubendorf, L
dc.contributor.authorEdelman, M J
dc.contributor.authorMarchetti, A
dc.contributor.authorMok, T
dc.contributor.authorNovello, S
dc.contributor.authorO'Byrne, K
dc.contributor.authorStahel, R
dc.contributor.authorPeters, S
dc.contributor.authorFelip, E
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2015-01-21T10:41:04Z
dc.date.available2015-01-21T10:41:04Z
dc.date.issued2014-09
dc.identifier.citationSecond ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. 2014, 25 (9):1681-90 Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid24718890
dc.identifier.doi10.1093/annonc/mdu145
dc.identifier.urihttp://hdl.handle.net/10541/338608
dc.description.abstractTo complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleSecond ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeenen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractTo complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.


This item appears in the following Collection(s)

Show simple item record